Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actoverco Filgrastim and Actoverco Pegfilgrastim versus Neupogen for prevention of chemotherapy-induced neutropenia in breast cancer
IRCT2013042212398N4Phase 3Completed
- Sponsor
- Actoverco
- Start
- Jan 2014
- Modality
- Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of filgrastim and pegfilgrastim in breast cancer and chemotherapy-induced neutropenia (CIN) (3 arms), sponsored by Actoverco. Primary endpoints: Effectiveness in preventing chemotherapy-induced neutropenia, Safety and 1 more. Started Jan 2014; status: completed.
02
Drugs
filgrastimpegfilgrastim
03
Conditions
breast cancerchemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on IRCT2013042212398N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2013042212398N4.